SCHEMBL6573334

SCHEMBL6573334

CC(C)S(=O)(=O)N[C@H]1CCC[C@H]1c1ccc(N(CC#N)Cc2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 13/20 0.60
GRIA2 P42262 8/20 0.53
KCNH2 Q12809 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6573331 1.00 GRIA4 (0.60) GRIA4GRIA2KCNH2
SCHEMBL6573336 0.86 GRIA4 (0.41) GRIA4GRIA2
SCHEMBL6573312 0.85 GRIA4 (0.61) GRIA4GRIA2KCNH2
SCHEMBL6573317 0.85 GRIA4 (0.61) GRIA4GRIA2KCNH2
SCHEMBL6573840 0.85 GRIA4 (0.60) GRIA4GRIA2KCNH2
SCHEMBL6573834 0.85 GRIA4 (0.60) GRIA4GRIA2KCNH2
SCHEMBL6762187 0.83 GRIA4 (0.58) GRIA4GRIA2KCNH2
SCHEMBL6762188 0.83 GRIA4 (0.58) GRIA4GRIA2KCNH2
SCHEMBL4606344 0.77 GRIA4 (1.00) GRIA4GRIA2KCNH2
SCHEMBL4605907 0.77 GRIA4 (1.00) GRIA4GRIA2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 GRIA4 9/4885GRIA2 7/4885KCNH2 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.